Reminder: Login to access new features and members-only content!

Register to be a member of our community. Its easy!

Register a new account

Already a member?

Log In here!

Donate

Did you find our content interesting or helpful? Help support the IPFD enhance health, well-being and welfare for dogs everywhere.

Jump to content
  •   Language
  • Sign Up

International Partnership for Dogs - Enhancing Dog Health, Well-Being, and Welfare - Join Us.

Leukocyte Adhesion Deficiency III (LAD3)

Breeds

Relevance Rating: Some evidence for test being meaningful in this breed

Relevance Rating: Unknown, not evaluated or no evidence for test for these breeds

General

Disease Name
Leukocyte Adhesion Deficiency III (LAD3)
Gene Name 2
Kindlin-3
Mutation
c.1349_1350insAAGACGGCTGC
Mutation 2
c.1358_1359insAAGACGGCTGCC
Test Type
Genetic Disease/Disorder
Details
Leukocyte Adhesion Deficiency III (LAD3) is considered a rare disease. Symptoms include: increased risk of infections, fever, lameness, and abnormal bleeding, including hemorrhage.
Details 2
Leucocyte adhesion deficiencies are inherited disorders characterised by immunodeficiency leading to recurrent infections and a marked leucocytosis. We describe the clinical characteristics... dog was investigated for pyrexia, persistent leucocytosis, marked periodontal disease, lameness, increased mucosal haemorrhages and poor wound healing. Numerous diagnostics were performed including a leucocyte adhesion deficiency III PCR test, which was positive... Leucocyte adhesion deficiency III is a rare disorder that manifests because of impaired activation of beta integrins. This results in an absence of neutrophil chemotaxis and adhesion, and platelet dysfunction... (From Hugo and Heading, 2014)
Published
Boudreaux, Mary K., et al. "A mutation in the canine Kindlin-3 gene associated with increased bleeding risk and susceptibility to infections." Thrombosis and haemostasis 103.2 (2010): 475-477.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.